Thom A. Reuvers

Rotterdam, ZH 3015CN, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

Radiosensitization of NET cells by HSP90 inhibitor ganetespib is mediated through pleiotropic stress responses.

Radiosensitization of NET cells by HSP90 inhibitor ganetespib is mediated through pleiotropic stress responses.

Journal: EJNMMI research
Published: August 06, 2025

A Reporter Platform to Study Therapy-Induced Senescence in Live Cancer Cells.

A Reporter Platform to Study Therapy-Induced Senescence in Live Cancer Cells.

Journal: Small methods
Published: June 27, 2025

Establishing In Vitro Dosimetric Models and Dose-Effect Relationships for 177Lu-DOTATATE in Neuroendocrine Tumors.

Establishing In Vitro Dosimetric Models and Dose-Effect Relationships for 177Lu-DOTATATE in Neuroendocrine Tumors.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: January 07, 2025

A Repurposed Drug Selection Pipeline to Identify CNS-Penetrant Drug Candidates for Glioblastoma.

A Repurposed Drug Selection Pipeline to Identify CNS-Penetrant Drug Candidates for Glioblastoma.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: October 25, 2024

Investigating the Radiobiological Response to Peptide Receptor Radionuclide Therapy Using Patient-Derived Meningioma Spheroids.

Investigating the Radiobiological Response to Peptide Receptor Radionuclide Therapy Using Patient-Derived Meningioma Spheroids.

Journal: Cancers
Published: June 10, 2024

DNA-PKcs inhibitors sensitize neuroendocrine tumor cells to peptide receptor radionuclide therapy in vitro and in vivo.

DNA-PKcs inhibitors sensitize neuroendocrine tumor cells to peptide receptor radionuclide therapy in vitro and in vivo.

Journal: Theranostics
Published: January 27, 2023

In Vivo Efficacy Testing of Peptide Receptor Radionuclide Therapy Radiosensitization Using Olaparib.

In Vivo Efficacy Testing of Peptide Receptor Radionuclide Therapy Radiosensitization Using Olaparib.

Journal: Cancers
Published: January 11, 2023

Radiolabeling and quality control of therapeutic radiopharmaceuticals: optimization, clinical implementation and comparison of radio-TLC/HPLC analysis, demonstrated by [177Lu]Lu-PSMA.

Radiolabeling and quality control of therapeutic radiopharmaceuticals: optimization, clinical implementation and comparison of radio-TLC/HPLC analysis, demonstrated by [177Lu]Lu-PSMA.

Journal: EJNMMI radiopharmacy and chemistry
Published: August 23, 2022

DNA Damage-Inducing Anticancer Therapies: From Global to Precision Damage.

DNA Damage-Inducing Anticancer Therapies: From Global to Precision Damage.

Journal: Cancers
Published: July 01, 2020
Showing 1-9 of 9

Last Updated: 09/26/2026